natgillin/translations-raw huggingface dataset:
primary (with no identified cause or familial);
primarna (brez ugotovljenega vzroka ali družinska),
primary (with no identified cause or inherited);
primarna (brez znanega razloga ali dedna);
primary (with no identified cause or inherited);
primarna (brez znanega vzroka ali dedna);
PRIMARY ANALYSIS
0,99 (0,88; 1,12)
PRIMARY ANALYSIS
1,01 (0,91; 1,12)
Primary Analysis ORR Intent- To-Treat Population (IRC)
Primarna analiza ORR populacije z namenom zdravljenja (IRC)
Primary analysis3
primarna analiza3
Primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukaemias; lymphoma; other conditions affecting the bone marrow or lymphatic system; immunosuppression due to HIV/AIDS (see sections 4.4, 4.8 and 5.1); cellular immune deficiencies.
Dedne in pridobljene imunske pomanjkljivosti zaradi stanj, kot so: akutne in kronične levkemije, limfomi, druga stanja, ki prizadenejo kostni mozeg ali limfatični sistem, imunosupresija zaradi okužbe z virusom HIV/AIDS (glejte poglavja 4.4, 4.8 in 5.1) in celična imunska pomanjkljivost.
primary blinded read / very conservative calculation (primary endpoint for STSG studies)
primarno slepo ocenjevanje / zelo konzervativen izračun (primaren cilj za študiji STSG)
Primary composite
Primarni sestavljeni
Primary composite endpoint
Primarni sestavljeni končni izid
Primary composite endpoint
Primarni sestavljeni opazovani dogodek
Primary Composite Endpoint at Week 32
Primarni sestavljeni cilj opazovanja po 32 tednih
Primary composite endpoint of CV death and heart failure hospitalisations*
primarni cilj opazovanja, sestavljen iz kardiovaskularne smrti in hospitalizacije zaradi srčnega popuščanja
Primary efficacy endpoint
Primarni cilj za oceno učinkovitosti
Primary Efficacy Endpoint (CV
Primarni opazovani
Primary efficacy endpoint was responder rate, defined as percentage showing ≥3-point improvement on the modified Teacher’s Drooling Scale (mTDS).
Končni cilj primarne učinkovitosti je bila stopnja odziva, opredeljena kot odstotek, ki je prikazoval izboljšanje v višini treh točk ali več po prilagojeni lestvici slinjenja Teacher's Drooling Scale (mTDS).
Primary efficacy endpoint was the proportion of subjects with short duration atrial fibrillation (3 hours to 7 days) who had a treatment-induced conversion of atrial fibrillation to sinus rhythm for a minimum duration of one minute within 90 minutes of first exposure to study drug.
Primarni opazovani dogodek učinkovitosti je bil delež preiskovancev s kratkotrajno atrijsko fibrilacijo (od 3 ure do 7 dni), pri katerih je bil z zdravilom dosežen prehod iz atrijske fibrilacije v sinusni ritem za vsaj eno minuto in v 90 minutah od prve izpostavljenosti raziskovanemu zdravilu.
Primary efficacy variables
Spremenljivke primarne učinkovitosti
Primary end-point in patients with renal impairment
Primarni opazovani dogodek pri bolnikih z okvaro ledvic
Primary Endpoint
Primarni cilj
Primary endpoint
Primarni cilj raziskave
Primary endpoint
Primarni kriterij
Primary Endpoint
Primarni opazovani dogodek Smrt/MI/IDR/ST
Primary Endpoint
Primarni opazovani dogodek Smrt/MI/IDR/STa
Primary Endpoint
Primarno končno stanje
Primary endpoint (flare)
primarni cilj opazovanja (zagon bolezni)
Primary Endpoint - Mean Change from baseline at Week 24
Primarni cilj – povprečna sprememba od začetka zdravljenja do 24. tedna
Primary endpoint a OR for response rates based on Mantel-Haenszel estimate of the common odds ratio for stratified tables; p-values by Cochran Mantel-Haenszel test.
primarna ocena učinkovitosti a OR za stopnje odziva na osnovi Mantel-Haenszelove ocene razmerja verjetnosti za stratificirane preglednice; p-vrednosti Cochran Mantel-Haenszelovega testa.
Primary endpoint a OR for response rates based on Mantel-Haenszel estimate of the common odds ratio for stratified tables; p-values by Cochran Mantel-Haenszel test.
Primarna ocena učinkovitosti a OR za stopnje odziva na podlagi Mantel-Haenszelove ocene razmerja obetov za stratificirane preglednice; p-vrednosti Cochran Mantel-Haenszelovega testa.
Primary endpoint a OR for response rates based on Mantel-Haenszel estimate of the common odds ratio for stratified tables; p-values by Cochran Mantel-Haenszel test. b Refers to response rate after second transplant for subjects who received a second transplant (42/240 [18% ] in BzmbDx group and 52/242 [21%] in VDDx group).
Primarna ocena učinkovitosti a OR za stopnje odziva na osnovi Mantel-Haenszelove ocene razmerja verjetnosti za stratificirane preglednice; p-vrednosti Cochran Mantel-Haenszelovega testa. b Nanaša se na stopnjo odgovora po drugi presaditvi pri posameznikih, pri katerih je bila le-ta izvedena (42/240 [18%] v skupini VcDx in 52/242 [21%] v skupini VDDx).
Primary Endpoint in FL population
Primarni opazovani dogodek v populaciji s FL
Primary endpoint in the sub-group of patients with renal impairment
Primarni opazovani dogodek v podskupini bolnikov z okvaro delovanja ledvic
Primary endpoint of study
Primarni opazovani dogodek v študiji
Primary endpoint of the study
Primarni opazovani dogodek v študiji
Primary endpoint was the proportion of patients in clinical remission at Week 52.
Primarni opazovani dogodek je bil delež bolnikov v klinični remisiji v 52. tednu.
Primary endpoint was the proportion of patients reaching HbA1c <7% without confirmed or severe hypoglycaemia.
Primarni opazovani dogodek je bil delež bolnikov, ki so dosegli HbA1c < 7 % brez potrjene ali hude hipoglikemije.
Primary endpoint:
Primarni opazovani dogodek:
Primary endpoint: Best recovery of VA (mean ± SE; 95%CI)
Primarni opazovani dogodek: najboljša povrnitev VA (povprečje ± SE; 95-% IZ)
Primary endpoint: Progression Free Survival (PFS, median in months)* Investigator Assessed **
Primarni cilj študije: preživetje brez napredovanja bolezni (mediana v mesecih)* raziskovalčeva ocena
Primary endpoint: proportion of subjects in sustained remission* at Week 52
Primarni cilj: delež oseb v trajnejši remisiji * po 52 tednih
Primary Endpoint: Proportion of Subjects with ≥75% improvement in PASI after 12 weeks of Treatment (PASI 75)
Primarni cilj študije: Delež bolnikov s ≥ 75 % izboljšanjem PASI po 12 tednih zdravljenja (PASI 75)
Primary Endpoint: Proportion of Subjects with ≥75% improvement in PASI after 12 weeks of Treatment (PASI 75)
Primarni cilj: Delež bolnikov s ≥ 75 % izboljšanjem PASI po 12 tednih zdravljenja (PASI 75)
Primary Endpointa, f
Primarni opazovani dogodeka, f
Primary endpoints
Primarni končni cilj
Primary endpoints included platelet count change from baseline in study C08-002A/B and thrombotic microangiopathy (TMA) event-free status in study C08-003A/B. Additional endpoints included TMA intervention rate, haematologic normalization, complete TMA response, changes in LDH, renal function and quality of life.
Primarna končna cilja sta vključevala spremembo števila trombocitov od izhodišča v študiji C08- 002A/B in stanje brez dogodkov trombotične mikroangiopatije v študiji C08-003A/B. Dodatni končni cilji so vključevali delež intervencij TMA, hematološko normalizacijo, popoln TMA odgovor, spremembe LDH, ledvično funkcijo in kvaliteto življenja.
Primary episodes occurred at a rate of 1.62% per patient-year in subjects treated with dapagliflozin and 2.06% in comparator-treatment subjects, per patient-year.
Delež primarnega dogodka je bil pri osebah, ki so prejemale dapagliflozin 1,62 % na bolnik- leto in pri osebah, ki so prejemale primerjalno zdravilo 2,06 % na bolnik-leto.
Primary G-CSF prophylaxis should be considered in patients who receive adjuvant therapy with TAC for breast cancer to mitigate the risk of complicated neutropenia (febrile neutropenia, prolonged neutropenia or neturopenic infection).
Primarna profilaksa z G-CSF pride v poštev pri bolnicah, ki prejemajo adjuvantno zdravljenje s TAC za raka dojke, za zmanjšanje tveganja zapletene nevtropenije (febrilne nevtropenije, dolgotrajne nevtropenije ali nevtropenične okužbe).
Primary G-CSF prophylaxis should be considered in patients who receive docetaxel, doxorubicin and cyclophosphamide (TAC) adjuvant therapy for breast cancer.
Pri bolnicah , ki prejemajo adjuvantno zdravljenje raka dojke z docetakselom, doksorubicinom in ciklofosfamidom (TAC), pride v poštev profilaksa z G-CSF.
Primary Generalised Tonic-Clonic Seizures
Primarni generalizirani napadi s tonično-kloničnimi krči
Primary hypercholesterolaemia and mixed dyslipidaemia in adults
Primarna hiperholesterolemija in mešana dislipidemija pri odraslih
Primary hypercholesterolaemia includes heterozygous familial (when the genetic abnormality is inherited from only one parent) and non-familial disease (when the genetic abnormality arises spontaneously without a family history).
Primarna hiperholesterolemija vključuje heterozigotno družinsko (kadar se genetska nepravilnost podeduje od samo enega starša) in nedružinsko bolezen (kadar se genetska nepravilnost pojavi spontano, brez družinske anamneze).
Primary immune thrombocytopenia (ITP)
Primarna imunska trombocitopenija (ITP)
Primary immune thrombocytopenia (ITP), a condition where the number of platelets in the blood stream is greatly reduced.
Primarna imunska trombocitopenija (ITP), pri kateri je število trombocitov v krvi močno zmanjšano.
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.
Primarna imunska trombocitopenija (ITP) pri bolnikih z velikim tveganjem za krvavitve ali pred kirurškim posegom za korekcijo števila trombocitov.
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.
Primarni imunski trombocitopeniji (ITP) pri bolnikih z velikim tveganjem za krvavitve ali pred kirurškim posegom za korekcijo števila trombocitov.
Primary Immunisation
Osnovna imunizacija
Primary immunodeficiency (PID) syndromes with impaired antibody production (see section 4.4).
Sindromih primarne imunske pomanjkljivosti (PID – Primary immunodeficiency syndromes) z okvarjenim nastajanjem protiteles (glejte poglavje 4.4).
Primary immunodeficiency syndromes with impaired antibody production (see section 4.4).
Sindromi primarne imunske pomanjkljivosti z okvarjenim nastajanjem protiteles (glejte poglavje 4.4).
Primary immunodeficiency syndromes with impaired antibody production (see section 4.4).
Sindromih primarne imunske pomanjkljivosti z zmanjšano tvorbo protiteles (glejte poglavje 4.4).
Primary means that the disease is generally the result of a genetic abnormality.
Primarna pomeni, da je ta bolezen običajno posledica genetske nepravilnosti.
Primary mutation other than Q148H/K/Ra
Druga primarna mutacija razen Q148H/K/Ra
Primary Outcome
Primarni izidi
Primary ovarian failure
primarna insuficienca jajčnikov,
primary ovarian failure
primarna odpoved jajčnikov
primary ovarian failure
primarni odpovedi jajčnikov
Primary ovarian failure.
primarna odpoved jajčnikov,
primary ovarian failure;
primarna odpoved jajčnikov
primary ovarian failure;
primarna odpoved jajčnikov;
Primary packaging material
Stična ovojnina
Primary PFS analysis Population
Populacija za primarno analizo PFS
Primary pharmacological activity (CCR5 receptor affinity) was limited in these species (see section 5.3).
Pri teh vrstah je bila primarna farmakološka aktivnost (afiniteta za CCR5 receptor) omejena (glejte poglavje 5.3).
Primary pharmacological activity (CCR5 receptor affinity) was limited in these species.
Pri teh vrstah je bila primarna farmakološka aktivnost (afiniteta za CCR5 receptor) omejena.
Primary Prevention of Venous Thromboembolism in Orthopaedic Surgery (pVTEp orthopaedic surgery)
Primarno preprečevanje venske trombembolije pri ortopedski operaciji (pVTEp pri ortopedski operaciji)
Primary Prophylaxis of Invasive Fungal Infections – Efficacy in HSCT recipients without prior proven or probable IFI
Primarna profilaksa invazivnih glivičnih okužb – učinkovitost pri prejemnikih HSCT brez predhodno dokazane ali verjetne IGO
Primary SEGA volume was reduced at month 6 compared to baseline (p<0.001 [see Table 5]).
Po 6 mesecih se je volumen primarnega SEGA zmanjšal v primerjavi z izhodiščno vrednostjo (p<0,001 [glejte preglednico 5]).
Primary Survival Analysis
Primarna analiza preživetja
Primary system organ class
Primarni organski sistem prednostni izraz
Primary tumor type
Vrsta primarnega tumorja
Primary tumour or tumour from a metastatic site was tested with a validated polymerase chain reaction (PCR) assay developed by Response Genetics Inc.
Primarni tumor ali tumor z metastatskega mesta so testirali z validiranim testom verižne reakcije s polimerazo (PCR), ki ga je razvila družba Response Genetics Inc.
Primary tumour or tumour from a metastatic site was tested with an investigational use only assay (IUO).
Primarni tumor ali tumor z metastatskega mesta so testirali s testom, ki je bil le za raziskovalno uporabo (IUO – investigational use only).
Primary tumour origin
primarni izvor tumorja
Primary tumour volume
Začetni volumen tumorja
Primary vaccination
Primarno cepljenje
Primary vaccination (individuals previously not vaccinated against smallpox): A first dose of 0.5 ml should be administered on an elected date.
Primarno cepljenje (posamezniki, ki še niso bili cepljeni proti črnim kozam): Prvi odmerek 0,5 ml je treba dati na izbrani dan.
Primary vaccination course with ProteqFlu-Te: first injection from 5-6 months of age, second injection 4-6 weeks later.
Primarno cepljenje s Proteqflu TE: prvi odmerek pri starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje.
Primary vaccination course with ProteqFlu-Te: first injection from 5–6 months of age, second injection 4-6 weeks later.
Primarno cepljenje s Proteqflu TE: prvi odmerek pri starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje.
Primary vaccination course with ProteqFlu-Te: first injection from 5–6 months of age, second injection 4–6 weeks later.
Primarno cepljenje s Proteqflu-TE: prvi odmerek pri starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje.
Primary vaccination course:
Osnovno cepljenje:
Primary vaccination course: first injection from 5 months of age, second injection 4-6 weeks later,
Primarno cepljenje: prvi odmerek od starosti petih mesecev, drugi odmerek 4 do 6 tednov pozneje.
Primary vaccination course: first injection from 5-6 months of age, second injection 4-6 weeks later.
Primarno cepljenje: prvi odmerek pri starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje.
Primary vaccination course: first injection from 6 months of age, second injection 3–5 weeks later.
Prvi krog cepljenja: prva injekcija od 6 meseca starosti, druga injekcija 3-5 tednov kasneje.
Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Osnovno cepljenje: prvi odmerek po 6 mesecih starosti, drugi odmerek 4 tedne pozneje.
Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Osnovno cepljenje: prvi odmerek po 6 mesecu starosti, drugi odmerek 4 tedne pozneje
Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Osnovno cepljenje: prvi odmerek po 6 mesecu starosti, drugi odmerek 4 tedne pozneje.
Primary vaccination of cats 9 weeks and older: two doses at an interval of 3 to 4 weeks.
Osnovno cepljenje mačk, starih 9 tednov in več: dva odmerka v intervalu 3 do 4 tednov.
Primary vaccination schedule
Osnovna shema cepljenja
Primary vaccination schedule
Shema osnovnega cepljenja
Primary vaccination scheme:
Osnovno cepljenje
Primary vaccination scheme: Two doses of Versican Plus DHPPi 3–4 weeks apart from 6 weeks of age.
Osnovno cepljenje: Dva odmerka Versican Plus DHPPi v razmaku 3–4 tednov od starosti 6 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus DHPPi/L4 3–4 weeks apart from 6 weeks of age.
Osnovno cepljenje: dva odmerka cepiva DHPPi/L4 v razmaku 3–4 tednov od starosti 6 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus DHPPi/L4R 3–4 weeks apart from 8–9 weeks of age.
Osnovno cepljenje: Dva odmerka cepiva DHPPi/L4R v razmaku 3–4 tednov od starosti 8–9 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus DHPPi/L4R 3–4 weeks apart from 8–9 weeks of age.
Osnovno cepljenje: Dva odmerka cepiva Versican Plus DHPPi/L4R v razmaku 3–4 tednov od starosti 8–9 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus L4 3-4 weeks apart from 6 weeks of age.
Osnovno cepljenje: Dva odmerka cepiva Versican Plus L4 v razmaku 3–4 tednov od starosti 6 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus L4 3–4 weeks apart from 6 weeks of age.
Osnovno cepljenje: Dva odmerka cepiva Versican Plus L4 v razmaku 3–4 tednov od starosti 6 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus Pi/L4 3–4 weeks apart from 6 weeks of age.
Osnovno cepljenje: Dva odmerka Versican Plus Pi/L4 v razmaku 3–4 tednov od starosti 6 tednov naprej.
Primary vaccination scheme: Two doses of Versican Plus Pi/L4R 3-4 weeks apart from 8-9 weeks of age.
Osnovno cepljenje: Dva odmerka cepiva Versican Plus Pi/L4R v razmaku 3–4 tednov od starosti 8–9 tednov naprej.
Primary vaccination:
Osnovno cepljenje
Primary vaccination:
Prvo cepljenje:
Primary vaccination: 2 injections of one dose (2 ml)
Primarno cepljenje: 2 injekciji enega odmerka (2ml)
Primary vaccination: first injection from 6 months of age onwards, second injection 3 to 5 weeks later.
Osnovno cepljenje: prva injekcija od 6 mesecev starost naprej, druga injekcija 3 do 5 tednov pozneje
Primary vaccination: Sows/gilts which have not yet been vaccinated with the product are given a primary injection 6 to 8 weeks before the expected date of farrowing and a second injection 4 weeks later.
Prvo cepljenje: Svinjam oz. mladicam, ki še niso bile cepljene, je prvi odmerek cepiva najbolje dati 6 do 8 tednov pred pričakovano prasitvijo, drugi odmerek pa 4 tedne po prvem.
Prime before each injection.
Aktivirajte peresnik pred vsakim injiciranjem.
Prime the pen.
Pripraviti peresnik.
Prime your KwikPen before each use.
Pred vsako uporabo svoj KwikPen pripravite.
priming dose
Primarni odmerek P/LAIV
Priming is complete when a stream of insulin appears from the needle tip.
Priprava je zaključena, ko iz konice igle priteče curek insulina.
Priming KwikPen
Priprava KwikPena
Priming should be performed in a well ventilated area.
je treba pršilo pripravljati v dobro prezračenem prostoru.
Priming to expel air prior to each injection
Priprava za odstranitev zraka pred vsakim injiciranjem
Priming your pen
Aktivacija peresnika
Priming your Pen
Priprava vašega peresnika
Priming your pen means removing the air from the needle and cartridge that may collect during normal use and ensures that the pen is working correctly.
Aktivacija zagotovi, da je peresnik pripravljen za uporabo in odstrani zrak, ki se lahko nabere v vložku pri običajni uporabi.
Priming your Pen means removing the air from the Needle and Cartridge that may collect during normal use and ensures that the Pen is working correctly.
Priprava peresnika pomeni, da ste iz igle in vložka odstranili ves zrak, ki se lahko nabere pri običajni uporabi; s tem zagotovite pravilno delovanje peresnika.
Principal toxicities included liver (liver enzyme elevations) at  20 mg/kg and  10 mg/kg, bone marrow (reduced platelet and white blood cell count)/hematologic at  20 mg/kg and  10 mg/kg, and lymphoid organs at  20 mg/kg and  3 mg/kg, in rat and monkey, respectively.
Glavni toksični učinki so prizadeli jetra (zvišanje jetrnih encimov) ob uporabi  20 mg/kg oz.  10 mg/kg, kostni mozeg (zmanjšanje števila trombocitov in belih krvnih celic)/hematološke vrednosti ob uporabi  20 mg/kg oz.  10 mg/kg ter limfatične organe ob uporabi  20 mg/kg oz.  3 mg/kg (vse prve vrednosti veljajo za podgane in vse druge za opice).
Printed carton containing one white high density polyethylene (HDPE) bottle with a child resistant closure, cotton colier and a desiccant canister.
Potiskana kartonska škatla z eno plastenko iz polietilena velike gostote (HDPE) s pokrovom, varnim pred otroci, vato in sušilnim sredstvom.
Printing ink
tiskarsko črnilo
Printing ink (Opacode S-1-15083): Shellac
Črnilo za tisk (Opacode S-1-15083): šelak
Printing ink black iron oxide (E 172) shellac propylene glycol ammonium hydroxide
Tiskarsko črnilo črn železov oksid (E 172), šelak, propilenglikol, amonijev hidroksid.
Printing ink containing Black iron oxide (E172) Shellac (E904)
Vsebina črnila črn železov oksid (E172) šelak (E904)
Printing ink containing shellac, propylene glycol and indigotine (E132) aluminium lake.
Črnilo vsebuje šelak, propilenglikol in indigotin (E132).
Printing ink containing: black iron oxide (E172), shellac (E904)
Vsebina črnila: črn železov oksid (E172), šelak (E904)
Printing ink Hypromellose (E464) Propylene glycol
Črnilo za potisk: Hipromeloza (E464) Propilen glikol
Printing ink Shellac
Tiskarsko črnilo
Printing ink Shellac
Črnilo za tisk šelak
Printing ink Shellac Glaze-45%
Tiskarska barva:
Printing ink shellac iron oxide black (E172) propylene glycol
Črnilo za tisk šelak črni železov oksid (E172) propilenglikol
Printing ink shellac iron oxide black (E172) propylene glycol (E1520)
Črnilo: šelak črni železov oksid (E172) propilen glikol (E1520)
Printing ink Shellac Propylene Glycol
Črnilo šelak,
Printing ink Shellac Propylene glycol
črnilo za napis na kapsuli šelak
Printing ink Shellac Propylene glycol Indigotine (E132)
Črnilo šelak propilenglikol indigotin (E132)
Printing ink shellac, black iron oxide (E172), propylene glycol
Črnilo natisnjene oznake šelak črni železov oksid (E 172) propilenglikol
Printing ink sunset yellow FCF (E110) latolrubine BK (E180) copper phthalocyanine blue pigment.
Tiskarsko črnilo oranžno barvilo FCF (E 110) latolrubin BK (E 180) modri pigment bakrovega ftalocianina
Printing ink: black iron oxide (E172), propylene glycol (E1520), shellac.
Črnilo za tisk: črni železov oksid (E172), propilenglikol (E1520), šelak.
Printing ink: Cochineal carminic acid (E120), Indigo carmine (E132), Titanium dioxide (E171) STOCRIN 100 mg hard capsules
Črnila za potisk: škrlatna karminska kislina (E120), indigotin (E132),titanov dioksid (E171) STOCRIN 100 mg trde kapsule
Printing ink: Cochineal carminic acid (E120), Indigo carmine (E132), Titanium dioxide (E171) SUSTIVA 100 mg hard capsules
Črnila za potisk: škrlatna karminsko kislino (E120), indigotin (E132), titanov dioksid (E171) SUSTIVA 100 mg trde kapsule
Printing ink: Iron oxide, red (E172)
Tiskarska barva: rdeči železov oksid (E172)
Printing ink: Shellac (E904) Dehydrated alcohol Isopropyl alcohol Butyl alcohol Propylene glycol Purified water
Tiskarsko črnilo: šelak (E904) dehidrirani alkohol izopropil alkohol butilni alkohol propilen glikol prečiščena voda
Printing ink: shellac (E904), dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, purified water, strong ammonia solution, potassium hydroxide, black iron oxide (E172), yellow iron oxide (E172), titanium dioxide (E171), dimethicone
Tiskarsko črnilo: šelak (E904), dehidrirani alkohol, izopropil alkohol, butilni alkohol, propilen glikol, prečiščena voda, koncentrirana raztopina amoniaka, kalijev hidroksid, črni železov oksid (E172), rumeni železov oksid (E172), titanov dioksid (E171), dimetikon
Printing ink: shellac glaze, black iron oxide (E172), and propylene glycol
Črnilo: šelak, črni železov oksid (E172) in propilenglikol
Printing ink: Shellac glaze, iron oxide black (E172), propylene glycol (E1520)
Tiskarsko črnilo: glazura iz šelaka, črni železov oksid (E172), propilenglikol (E1520)
Printing ink: shellac glaze-45%, black iron oxide (E172), propylene glycol, ammonium Hydroxide 28%.
Tiskarska barva: šelak-45%, črni železov oksid (E172), propilenglikol, 28% amonijev hidroksid.
Printing ink: shellac, black iron oxide (E172), propylene glycol, ammonia solution, potassium hydroxide.
Tiskarska barva: šelak, črni železov oksid (E172), propilenglikol, raztopina amonijaka, kalijev hidroksid
Printing ink: Shellac, black iron oxide, and potassium hydroxide
Črnilo: šelak, črni železov oksid in kalijev hidroksid
Printing ink: shellac, indigo carmine aluminium lake (E132)
Črnilo za napis: šelak, indigotin (E132).
Printing ink: Shellac, iron oxide black (E172), propylene glycol (E1520)
Črnilo: šelak, črni železov oksid (E172), propilenglikol (E1520)